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Abstract
Introduction Infective endocarditis (IE) is associ-
ated with a high in-hospital and long term mortality.
Although progress has been made in diagnostic ap-
proach and management of IE, morbidity and mor-
tality of IE remain high. In the latest European guide-
lines, the importance of the multi-modality imaging
in diagnosis and follow up of IE is emphasized.
Aim The aim was to provide information regarding
mortality and adverse events of IE, to determine IE
characteristics and to assess current use of imaging in
the diagnostic workup of IE.
Methods This is a prospective observational cohort
study. We used data from the EURO-ENDO registry.
Seven hospitals in the Netherlands have participated
and included patients with IE between April 2016 and
April 2018.
Electronic supplementary material The online version of
this article (https://doi.org/10.1007/s12471-020-01431-z)
contains supplementary material, which is available to
authorized users. A complete list of the EURO-ENDO
Investigators Group and of the EURO-ENDO National
Coordinators is provided in the ESM.
S. El Kadi · D. M. F. van den Buijs · T. Meijers · O. Kamp ()
location VU University Medical Centre, Department of
Cardiology, Amsterdam UMC, Amsterdam University
Medical Centers, Amsterdam, The Netherlands
o.kamp@amsterdamumc.nl
M. D. Gilbers
Department of Cardiothoracic surgery, Maastricht UMC,
Maastricht University Medical Center+, Maastricht, The
Netherlands
S. C. A. M. Bekkers
Department of Cardiology, Maastricht UMC,Maastricht
University Medical Center+, Maastricht, The Netherlands
Results A total of 139 IE patients were included.
Prosthetic valve endocarditis constituted 32.4% of
the cases, cardiac device related IE 7.2% and aortic
root prosthesis IE 3.6%. In-hospital mortality was
14.4% (20 patients) and one-year mortality was 21.6%
(30 patients). The incidence of embolic events under
treatment was 16.5%, while congestive heart failure or
cardiogenic shock occurred in 15.1% of the patients.
Transthoracic and transoesophageal echocardiogra-
phy were performed most frequently (97.8%; 81.3%)
and within 3 days after IE suspicion, followed by
18F-fluorodeoxyglucose positron emission tomogra-
phy/computed tomography (45.3%) within 6 days
and multi-slice computed tomography (42.4%) within
7 days.
Conclusion We observed a high percentage of pros-
thetic valve endocarditis, rapid and extensive use of
imaging and a relatively low in-hospital and one-year
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What’s new?
 This is a prospective multi-centre observational
study on infective endocarditis in the Nether-
lands
 One-third of the patients have prosthetic valve
endocarditis
 Transthoracic and transoesophageal echocar-
diography are frequently used for the diagnostic
workup (97.8% and 81.3% with at least one ex-
amination), followed by PET-CT (45.3%)
 Surgery is performed in 50.1% of the patients,
more than half of these patients received early
surgery (i.e. <14 days)
 In-hospital mortality is 14.4% and 1-year mortal-
ity is 21.6%
mortality of IE in the Netherlands. Limitations include
possible selection bias.
Keywords Infective endocarditis · Dutch registry ·
Prosthetic valve endocarditis · Imaging · Mortality
Introduction
Infective endocarditis (IE) is an infectious disease
with high mortality and morbidity [1]. The epi-
demiologic profile of IE has changed over the past
decades. While IE previously affected young patients
with preexisting (rheumatic) valvular abnormalities
[2], current risk factors include exposure to health
care associated procedures, old age, prosthetic valves
and intracardiac devices [3, 4]. The exact incidence
of IE is difficult to determine since definitions of IE
have changed over time. In the Netherlands, a ret-
rospective epidemiological study demonstrated an
increase in incidence of IE from 2005 till 2011 [5],
coinciding with the more restrictive use of antibi-
otic prophylaxis as recommended by the European
Society of Cardiology (ESC) [6]. In the 2015 ESC
guidelines a number of preventive, diagnostic and
therapeutic adjustments were proposed [7]. Some of
the key recommendations were early transthoracic
(TTE) and transoesophageal echocardiography (TOE)
and early surgery for prevention of heart failure, struc-
tural damage and embolic events. More importantly,
novel major criteria have been added to the modi-
fied Duke criteria. The modified ESC 2015 diagnostic
criteria now includes paravalvular lesions identified
with cardiac computed tomography (cardiac CT) and
abnormal activity around the implantation site of
prosthetic valves seen with 18F-fluorodeoxyglucose
positron emission tomography/computed tomogra-
phy (18F-FDG PET/CT). In aortic IE, cardiac CT has
the advantage of providing information regarding the
extent of IE as well as the anatomy of the aortic struc-
tures and coronary arteries before surgery. The use of
additional imaging modalities allows for earlier and
reliable diagnosis of IE, particularly in the setting of
prosthetic valves or when echocardiography is incon-
clusive [8]. Also, since IE may present with different
symptoms depending on the affected organs and
complications, a multidisciplinary approach is essen-
tial. Early and regular discussion of IE patients in the
Endocarditis Team may lead to early additional imag-
ing and correct interpretation, altered antimicrobial
strategies and early surgery. Different observational
studies suggested that a collaborative approach by an
Endocarditis Team results in a lower mortality [9, 10].
Current in-hospital mortality rate is being estimated
at approximately 20% [1, 11]. In the Netherlands,
there are no recent data regarding in-hospital and
one-year mortality. We aim to provide information
regarding mortality and adverse events of IE in the
Netherlands and assess IE characteristics and current
use of imaging modalities in the diagnostic workup
of IE. The outcome of this study may contribute to
a better insight in present IE profile and clinical prac-
tice and provide outcomes on hard clinical endpoints
in light of the recent changes in IE management.
Methods
We conducted a prospective observational multi-cen-
ter cohort study using data of the European Endo-
carditis Registry (EURO-ENDO). This registry has been
initiated by the ESC with the aim to study the current
diagnostic and therapeutic practice of IE across Eu-
rope and outside. Patients aged eighteen years and
over with definite IE or possible IE (according to the
modified ESC 2015 diagnostic criteria) were included
in the EURO-ENDO. Inclusion was between April 2016
and April 2018. Follow up lasted until April 2019. In
the Netherlands, seven hospitals with a combined ad-
herence region of 8 million inhabitants, participated
in the EURO-ENDO registry. Each center included pa-
tients in a time frame of one year. Variables that were
collected include demographics, relevant pre-existing
valve conditions, laboratory and imaging findings, an-
timicrobial therapy, surgery and follow up. Approval
of the medical ethics committee was obtained before
data collection in all centers. All participating patients
provided informed consent.
The primary endpoint is in-hospital and one-year
mortality. Secondary endpoints are incidence of em-
bolic events, congestive heart failure and cardiogenic
shock during hospital stay.
Descriptive summaries of the data are presented.
Continuous variables are expressed as mean and
standard deviation or median and interquartile range.
Categorical variables are expressed in percentages.
Student’s t-test or non-parametric tests were used to
compare continuous data between groups, Fisher’s
exact test to compare categorical data. In addition,
we performed multivariable analyses using logistic
regression to correctly assess association between the
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Between 2016 and 2018, 139 patients from the Nether-
lands have been included in the EURO-ENDO registry.
From these patients, approximately 40% were referred
from regional hospitals to one of the participating car-
diac surgery hospitals. The clinical characteristics of
the patients are presented in Tab. 1. The majority
of the patients were men (68.3%) with a median age
of 64 years (IQR 57.0–75.0). Of the patients present-
ing with IE, 9 patients (6.5%) had a previous episode
of endocarditis. Approximately one third (33.8%) had
previous valve surgery. At presentation, 33.1% of the
patients had a prosthetic valve. Three patients (2%)
had previous trans-aortic valve implantation. A car-
diac device was in place in 17 patients (12.2%). Ten
patients (14.1%) had a congenital heart disease. There
were 117 patients (83.5%) with definite IE and 22 pa-
tients (16.5%) with possible IE.
Microbiology
Of the patients with IE, 91.4% had positive blood cul-
tures. In 76.3% of the cases the blood cultures met
the major criterium of the modified Dukes criteria,
whereas 15.1% fulfilled the minor criterium. Staphylo-
coccus aureus (SA) was the most frequently cultured
micro-organism (31 patients; 22.3%). As a group,
the streptococci were most prevalent (42.4%). There
were 35 patients with streptococcus viridans (25.2%).
Among the other cultured pathogens were entero-
cocci (11.5%), Propionibacterium acnes (n= 2) and
gram negative bacilli (n=2). Streptococcus related
IE was seen more often in NVE compared with PVE
(48% vs. 31.7%, P= 0.09; Suppl. Table 3). Enterococci
and coagulase negative staphylococci were more fre-
quently found in PVE patients (19.5% vs. 8.2%, P= 0.08
and 14.6% vs. 2.0%, P< 0.01 respectively).
Table 2 Use and timing of imaging
Imaging modality No of patients with at least
one exam performed (%)
Median time (days) after date of suspected IE
(IQR)
Totala NVE PVE P-value
Transthoracic echocardiography (TTE) 136 (97.8) 84 (98.8%) 44 (97.8%) >0.999 0 (0–2)
Transoesophageal echocardiography
(TOE)
113 (81.3) 65 (76.5%) 37 (82.2%) 0.056 3 (1–6)
Multislice CT-scan (total) 59 (42.4) 32 (37.6%) 25 (55.6%) 0.064 5 (1–11)
Multislice CT-scan (cardiac) 37 (26.6) 20 (23.5%) 16 (35.6%) 0.155 7 (2–12)
MRI (total) 31 (22.3) 18 (21.2%) 10 (22.2%) 0.665 2 (–1–6)
FDG PET-CT scan 63 (45.3) 26 (30.6%) 27 (60.0%) <0.001 6 (3–10)
Values expressed as median (interquartile range)
aCardiac-device related IE (CDRIE) cases are also included in the total group
Table 1 Baseline characteristics
Characteristics N= 139 (%)
Male 95 (68.3)
Mean age 63.9 (57.0–75.0)
Previous endocarditis 9 (6.5)
Congenital heart disease 14 (10.1)
Previous valve surgery 47 (33.8)
Prosthetic valve at admission 46 (33.1)
Device therapy at admission 17 (12.2)
Positive culture 127 (91.4)
Positive culture, major criterium 106 (76.3)
Positive culture, minor criterium 21 (15.1)




Native valve endocarditis 85 (61.2)
Prosthetic valve endocarditis 45 (32.4)
Cardiac device related IE 10 (7.2)
Aortic root/ascending aorta prosthesis IE 5 (3.6)
Aortic valve IE 87 (62.6)
Mitral valve IE 41 (29.5)
Pulmonary valve IE 6 (4.3)
Tricuspid valve IE 3 (2.2)
Surgery 70 (50.4)
Possible IE 23 (16.5)
Definite IE 116 (83.5)
Values expressed as N (percentage) and median (interquartile range)
Affected valves
NVE represented 56.8% of the cases, while 32.4% of
the patients had PVE.We also observed 10 cases (7.2%)
of cardiac device related IE (CDRIE) and 5 cases (3.6%)
of IE of the aortic root or ascending aorta prosthesis.
In 87 patients (62.6%), the aortic valves were affected.
Mitral valves were affected in 41 patients (29.5%). Pul-
monary and tricuspid valves were affected in 4.3% and
2.3% of the patients respectively. Combined aortic and
mitral valve IE occurred in 15 patients (10.8%).
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Fig. 1 Types of surgical intervention in aortic and mitral valve
Imaging
Various imaging modalities were used for diagnosing
IE (Tab. 2). Transthoracic echocardiography (TTE)
was performed at least once in 136 patients (97.8%)
and transoesophageal echocardiography (TOE) in 113
patients (81.3%). Overall use of multislice computed
tomography (MS-CT) was 42.4%, the use of cardiac
MS-CT scan was 25.9%. Thirty-one patients (22.3%)
had an MRI-scan to detect embolic complications.
Fifteen patients had an MRI scan of the brain and
18 patients had an MRI scan of the spine. One MRI
scan of the abdomen was made. Cardiac MRI was
not performed. 18F-FDG PET/CT scan was performed
significantly more often in patients with prosthetic
valves or devices compared to NVE patients (60.0%
vs. 30.6%, P< 0.001). In total 63 patients (45.3%) re-
ceived a 18F-FDG PET/CT scan. TTE was usually per-
formed the same day that the diagnosis IE was sus-
pected (0–2). The median time until performing TOE
was three days (1–6). Cardiac MS-CT was performed
after 7 days (2–11.8), PET-CT scan after 6 days (3–10).
Surgery
A total of 70 patients (50.4%) underwent surgical in-
tervention, i.e. valve surgery or lead removal (Tab. 1).
Median time to surgery was 13 days (6–27) after
suspected IE diagnosis. Urgent surgery, defined as
surgery within 7 days, was performed in 21 patients
(15.1%). Early surgery, defined as surgery within




Embolic events 23 (16.5) 9 (10.6) 11 (24.4) 0.044
Congestive heart failure or cardiogenic shock 21 (15.1) 17 (20) 2 (4.4) 0.018
Thirty day mortality 11 (7.9) 8 (9.4) 2 (4.4) 0.492
In-hospital mortality 20 (14.4) 11 (12.9) 8 (17.8) 0.449
1-year mortality 30 (21.6) 17 (20.0) 11 (25.0) 0.509
14 days, was performed in 37 patients (26.6%). The
most frequently performed procedures were aortic
valve surgery (54 patients; 38.8%) and mitral valve
surgery (19 patients; 13.7%). Bioprosthetic aortic
valve replacement was performed in 36 of the 54 aor-
tic valve procedures (66.7%, Fig. 1). Mitral valve repair
was performed in 12 of the 19 mitral valve procedures
(63.2%).
Main outcomes
In-hospital all-cause mortality was 14.4% (median
time between suspected IE diagnosis and in-hospital
mortality was 30 days, IQR: 14–48) and one-year mor-
tality was 21.6% (see Tab. 3). In-hospital mortality did
not differ significantly between surgically and conser-
vatively treated patients (12.9% vs. 15.9%, P= 0.391).
The incidence of embolic events under treatment was
16.5%. Embolic events were more prevalent in PVE
compared to NVE (24.4% vs. 10.6%, P=0.044). Con-
gestive heart failure or cardiogenic shock occurred
in 15.1% of the patients, significantly more in NVE
patients compared to PVE (20.0% vs. 4.4%, P= 0.018).
Three patients with cardiogenic shock died in hos-
pital. Of the 23 patients with embolic events during
treatment, 7 patients had an indication for surgery
but did not receive surgery (because of surgical risk
or neurologic complication). Of these 7 patients that
were treated conservatively, 5 patients died in-hospi-
tal.
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Prognostic factors
Univariate analysis was performed to assess associ-
ation between individual variables and clinical out-
come (Suppl. Table 1). The mean age of patients
who deceased in-hospital was 72 years, whereas the
mean age of the patients who survived was 63 years
(P= 0.019, 95% CI: 1.52–16.35). Age was associated
with in-hospital mortality with an odds ratio of 1.050
per life year. Using multivariate analysis, embolic
events during treatment was identified as an inde-
pendent prognostic factor for in-hospital mortality
(OR= 5.551, 95% CI: 1.862–16.547, P=0.002). SA en-
docarditis was also found to be an independent risk
factor (OR= 4.205, 95% CI: 1.468–12.043, P= 0.007).
PVE, timing to imaging, surgery and timing to
surgery were not associated with increased mortal-
ity. Female sex showed a trend towards significant
association with in-hospital mortality (P=0.062).
Female patients were more likely to have SA en-
docarditis compared to men (OR= 2.554, 95% CI:
1.121–5.861, P= 0.029) and tended to develop embolic
complications during treatment more often than men
(P= 0.068), both which are associated with higher in-
hospital mortality.
Discussion
Since the analysis of bacterial endocarditis by Van der
Meer et al. in 1992 this is the first prospective study
examining the current mortality of IE in the Nether-
lands [12]. We observed a relatively low in-hospital
mortality of 14.4% and a one-year mortality of 21.6%.
In a recent study in a single center without cardiac
surgery facilities in the Netherlands, an in-hospital
mortality of 18% was reported [13], while other stud-
ies reported a one-year mortality around 30% [14, 15].
The group patients that were included in our study
were patients in tertiary hospitals with cardiac surgery
facilities. This difference in patient population might
account for differences in mortality.
Furthermore, reported complications of IE include
embolization and heart failure due to valve destruc-
tion. A higher incidence of embolic events was ob-
served in PVE patients compared to NVE. It must be
noted however, that 18F-FDG PET/CT imaging was sig-
nificantly more often performed in PVE than in NVE,
which may have resulted in more (silent) embolus de-
tection. Conversely, we found more congestive heart
failure and cardiogenic shock in NVE. Patients with
NVE referred to tertiary centers are more likely to suf-
fer from progressive IE, valve destruction and consec-
utive heart failure. Because previous studies showed
worse prognosis of PVE [16, 17], physicians may treat
patients with prosthetic valves and signs of infection
more cautiously resulting in early referral and ade-
quate therapy in a timely fashion.
The results of this study implicate a rapid use of
imaging modalities once IE is suspected. TTE is usu-
ally performed on the same day of cardiologic con-
sultation and TEE follows within a week with a me-
dian duration of three days. Although we did not find
a significant association between timing of imaging
and mortality, prompt timing of imaging is crucial for
early decision-making. Another finding with regard to
imaging is the extensive use of 18F-FDG PET/CT scan.
Knowing that 18F-FDG PET/CT scan has proven its
added value in diagnosing PVE and CDRIE as well as
in detecting embolic events, further use of this imag-
ing modality may aid in correct diagnosis of IE [8].
Moreover, Swart et al. suggested early use of 18F-FDG
PET/CT can increase diagnostic performance in PVE
[18]. With a median of six days after IE suspicion,
18F-FDG PET/CT is also rapidly and consistently used.
Interestingly, valve surgery has been carried out in
half of the patients referred to cardiac surgery cen-
ters. Improved identification of patients eligible for
surgery may have contributed to this number. Early
surgery has been shown to decrease the composite
endpoint of death from any cause and embolic events
[19]. In our study, a large distribution is seen in timing
of surgery, varying from 1 to 71 days with a median of
13 days after suspicion of IE. Of the patients who un-
derwent surgery, more than half received early surgery
(<14 days). In patients with aortic valve endocardi-
tis who went for surgery, bioprosthetic aortic valves
were the most frequently used followed by mechanical
valves. In patients with infected mitral valves, mitral
valve repair was the most commonly performed pro-
cedure, which may be related to less valve destruction
at time of presentation and ease of surgery. Surgery
on patients despite embolic events when indication
for surgery exists (i.e. heart failure, uncontrolled in-
fection, abscess or persistent high embolic risk) can
be done with low neurological risk, provided cerebral
hemorrhage has been excluded on cranial CT [20].
The threshold for surgery in these patients appears
high, as one third of the patients with embolic events
and indication for surgery have been treated conser-
vatively, mostly because of neurologic complication.
The outcome of the non-surgically treated patients
with embolic events and indication for surgery is poor,
72% died in hospital.
An Endocarditis Team has been reported to reduce
mortality in IE patients, although these results stem
from historical control data [21, 22]. In the most re-
cent update of the guidelines for the management of
patients with endocarditis, the constitution of an En-
docarditis team is recommended as a crucial part in
the improvement of care for patients with IE. In five of
the seven participating centers in the Netherlands, pa-
tients were discussed in an Endocarditis Team. In the
other two hospitals patients were discussed in a heart
team with consultation of an infectiologist and a med-
ical microbiologist. This multidisciplinary approach
may have positively influenced patient outcome.
Looking at the epidemiological characteristics, we
see a relatively high proportion of PVE (33.1%). An
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in-hospital mortality of 22.8% has been reported in
PVE [23]. We did not observe an association between
PVE and in-hospital or one-year mortality. SA endo-
carditis is known to increase the risk of in-hospital
mortality [24]. Its frequency has risen worldwide over
the past decades up to 30%, pre-dominantly driven
by SA endocarditis increase in North America (>50%).
In Europe current frequency of SA endocarditis is be-
tween 20–30% with no clear alteration in the last two
decades [25, 26]. In the present study, SA endocarditis
comprised 21.6% of the IE population in the Nether-
lands.
Other baseline characteristics like median age,
male to female ratio and percentage positive blood
cultures are comparable with previous reports (Suppl.
Table 2).
As pointed out earlier, limitations of this registry
include the possible selection bias. We identified only
those patients referred to a larger hospital with a car-
diac surgery department, for evaluation of IE. Patients
in non-cardiac surgery hospitals not needed to be
transferred were not included in the present study.
This might have influenced the patient characteristics
and therefore the effect on mortality can be ambigu-
ous; patients with uncomplicated IE with a small veg-
etation and no indication for surgery are not included
and therefore real mortality may be even lower. On
the other hand, patients not suitable for surgery be-
cause of age, comorbidity or complications and possi-
bly a worse predicted outcome may not have been re-
ferred. Including these patients would imply a higher
mortality. Furthermore, patients who were critically ill
(e.g. clinical unstable patients or treated with a ven-
tilator) at admission and who were not able to give
informed consent were also not included. Lastly, due
to the limited number of hospitals that participated
in the EURO-ENDO study and the varying period of
inclusion, we could not comment on the incidence of
IE.
Recently the EURO-ENDO registry has been com-
pleted and prospective data on IE profile and outcome
in different countries are now available [26]. Com-
pared to the European cohort similar results are seen
with regard to age, prosthetic valve endocarditis and
surgery rate. Differences are observed regarding imag-
ing; TOE and 18F-FDG PET/CT are more frequently
used in the Netherlands. Moreover, the in-hospital
mortality of IE in the Dutch cohort is slightly lower
than the mortality in the overall EURO-ENDO cohort
(14.4% vs. 17.1%).
Conclusion
A relatively low in-hospital and one-year mortality
was observed in patients with IE in the Netherlands,
despite the large group of PVE and SA endocarditis.
Multiple changes in recent years could be the cause;
the multidisciplinary management by an Endocarditis
Team, the early and extensive use of imaging and the
relatively high rate of (early) surgery. However, while
the low encountered mortality may indicate a leap in
the good direction since the last decades of IE man-
agement, we must be careful in drawing conclusions,
as some results may be affected by patient selection
bias. Further research with inclusion of patients in
non-cardiac surgery hospitals is necessary to confirm
our findings.
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